05.29.25 -- Squeezing CDMOs Dry? One Big Pharma VP Says Enough Is Enough

We know how tough it can be to find the right CDMO, especially when capacity is tight and timelines are critical. That's why you’ll find our collection of recent Outsourced Pharma Capacity Update presentations so valuable. Our April Partners Week Update details the latest capabilities and available capacity from 40 leading CDMOs – and you can experience it all from the convenience of your screen. View the on-demand sessions for the modalities that fit your needs.

Due to the growing demand for biotech innovations, many industry stakeholders turn to CDMOs to manage the complexity and cost of drug development and manufacturing.

Delve into the specific challenges encountered in the development of high-concentration formulations and gain an overview of current state-of-the-art solutions for subcutaneous administration.

The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?

The radiotherapy company's novel SADA construct uses self-assembling tetramers to deliver isotopes directly to cancer cells for a highly targeted, less toxic treatment.

Capacity constraints typically are accompanied by other challenges, including missed timelines, defect rates, and overall decreased satisfaction with pharma companies’ bioprocessing CDMOs.

Take a closer look at the evolution and future potential of microbial manufacturing to uncover how digital tools can revolutionize development and production processes.

High-quality process development aims to maintain a consistent process from toxicology through to GMP production runs, and can be aided by a capable, adaptable CDMO.

Explore challenges in today’s changing market and solutions to help successfully develop and manufacture lifesaving products.

The need for manufacturing support that offers adaptable, scalable solutions has become more crucial than ever for the diagnostic space.

This advanced cell line development technology overcomes production challenges related to the expression and scalability of complex biologics.

This solution enhances efficiency by streamlining timelines and reducing risks in downstream processes. It helps developers navigate the IND pathway more effectively and meet critical milestones.

Leverage robust development strategies and enable an optimized process for mAb development and manufacturing, efficiency, and speed with exceptional quality, and high titers with lower-cost workflows.

Our expertise and capabilities allowed us to produce our own HEK293 production cell lines utilizing a wide variety of upstream platforms including iCellis, Cell Stacks, Univercells, and Stirred-Tank Reactors.

Witness how our proven expertise and simplified execution with development, filling, and analytical under one roof ensure safe, efficacious products reach patients in need.

Compatible with various host cell lines, works across multiple vector configurations, this platform for antibodies with increased ADCC activity reduces core fucose within any cell line.

Whether you aim to launch your innovative product on a global scale, enhance your formulation, or proactively manage risks, Simtra is here to support you in fulfilling your commitments to patients.

Our Drug Product Services (DPS) delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.